Revolution Medicines, Inc.
NASDAQ:RVMDBiotechnology
+$3.60 today
- Market cap
- $34.57B
- Beta
- 1.41
- P/E (TTM)
- -23.3
- EPS (TTM)
- -$6.92
Volume 2.34M
Average 3.10M
RVMD Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Revolution Medicines, Inc.NASDAQ: RVMD
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses turns negative
Q2 FY2026 other income / expenses was -$139.24M, compared with $16.93M a year earlier. Trailing-twelve-month other income / expenses was -$141.04M. Over 3 fiscal years it compounded at +77.4% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near -$139.24M or moves back toward the trailing-twelve-month quarterly average of -$35.26M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 51.07M USD
- Year-over-year change
- -42.4%
- 4-year CAGR
- +173.2%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.07M | -42.4% |
| FY2024 | 2024-12-31 | 88.68M | +87.5% |
| FY2023 | 2023-12-31 | 47.29M | +416.6% |
| FY2022 | 2022-12-31 | 9.15M | +898.3% |
| FY2021 | 2021-12-31 | 917K | — |
Other Income / Expenses vs competitors
How RVMD compares with its peers on the latest reported figures
- RVMD's LTM Jun 2026 other income / expenses of -$141.04M is the lowest of the 11 companies compared; the peer median is $17.48M.
- Its year-over-year change of -266.5% is the 10th highest of 11, against a peer median of -6.5%.
- Over three fiscal years its annual growth of +77.4% compares with a peer median of +55.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $43.41M | -19.7% | +128.0% | 19.3% | |
| LTM Jun 2026 | $24.4M | -22.6% | +44.2% | 235.7% | |
| LTM Sep 2026 | $21.88M | +45.3% | +141.8% | — | |
| LTM Sep 2026 | $20.48M | +106.3% | +48.7% | — | |
| LTM Aug 2026 | $18.56M | -20.1% | +84.3% | 2.6% | |
| LTM Mar 2026 | $16.4M | +41.5% | +55.1% | 38.2% | |
| LTM Mar 2026 | $14.69M | +6.7% | +72.3% | — | |
| LTM Mar 2026 | $10.06M | +10.6% | +14.6% | — | |
| LTM Mar 2026 | -$23.11M | -31.1% | — | 46.6% | |
| LTM Sep 2026 | -$130.29M | -898.0% | +13.9% | — | |
| LTM Jun 2026 | -$141.04M | -266.5% | +77.4% | — | |
| Peer median (excluding RVMD) | $17.48M | -6.5% | +55.1% | 38.2% | |
Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 29.39M | 35.38M | 11.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 16.56M |
| Gross Profit | 29.39M | 35.38M | 11.58M | 0 | (16.56M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 186.95M | 253.07M | 423.14M | 592.23M | 978.68M |
| Selling, General & Admin | 30.45M | 40.59M | 75.62M | 97.3M | 187.13M |
| Operating Expenses | 217.4M | 293.66M | 498.77M | 689.52M | 1.17B |
| Depreciation & Amortization | 7.33M | 9.66M | 9.31M | 11.82M | 16.56M |
| EBITDA | (179.75M) | (239.47M) | (430.28M) | (589.02M) | (1.09B) |
| EBITDA Margin | -611.6% | -676.8% | -3715.7% | — | — |
| Operating Income | (188.01M) | (258.28M) | (487.19M) | (689.52M) | (1.18B) |
| Operating Margin | -639.7% | -730.0% | -4207.1% | — | — |
| Interest Income | 929K | 9.15M | 47.48M | 86.88M | 90.69M |
| Interest Expense | 12K | 0 | 303K | 0 | 24.23M |
| Other Income / Expenses | 917K | 9.15M | 47.29M | 88.68M | 51.07M |
| Income Before Tax | (187.09M) | (249.13M) | (439.89M) | (600.85M) | (1.13B) |
| Pre-Tax Margin | -636.6% | -704.1% | -3798.7% | — | — |
| Income Tax Expense | 0 | (420K) | (3.52M) | (753K) | 0 |
| Net Income | (187.09M) | (248.71M) | (436.37M) | (600.09M) | (1.13B) |
| Net Margin | -636.6% | -703.0% | -3768.3% | — | — |
| EPS (Basic) | (2.47) | (3.08) | (3.86) | (3.58) | (5.95) |
| EPS (Diluted) | (2.47) | (3.08) | (3.86) | (3.58) | (5.95) |
| Weighted Avg Shares | 72.81M | 80.63M | 113.15M | 167.74M | 190.13M |
| Weighted Avg Shares (Diluted) | 72.81M | 80.63M | 113.15M | 167.74M | 190.13M |
Revolution Medicines, Inc.
NASDAQ:RVMD
Intrinsic Alpha fair value
Locked
Current Price
$159.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.